INDUSTRIES · PHARMA

Start with the plants no one has characterized.

Prioritize species, compounds, and mechanisms before the lab. Develop the candidate to extract, fraction, or molecule.

Why it's hard today

01

Discovery is slow, expensive, and uncertain

Most natural candidates are ruled out late, after the budget is gone.

02

Latin American chemistry is underrepresented

Much of the region's flora has never been characterized, so it rarely enters a pipeline.

03

IP decides early

A promising candidate with no room to protect it is a candidate you can't move forward.

What you can do with Moka

With the platform · Moka BDE

  • Predict bioactivity, even in plants with no prior studies.
  • Understand likely mechanisms and targets before testing.
  • Assess patentability and freedom to operate early.
  • Connect your experimental data to what is known about each plant.

Questions you can bring us

Every project starts with a question. These are the kind we hear.

  • “Which Latin American species could act on this target?”
  • “What mechanism could explain this extract's activity?”
  • “Is there freedom to operate for this molecule?”
  • “Which understudied family should we explore first?”
Related research The genes behind quinine, an Andean plant compound (Nature, 2026)

Frequently asked questions

Does Moka run clinical trials?

No. Moka works in early discovery: prioritizing and developing candidates up to extract, fraction, or molecule.

Does Moka have its own candidates?

Yes. We have a patent pending for an immunomodulator candidate identified through our discovery pipeline.

Are predictions validated?

Predictions are hypotheses to prioritize. Our R&D service takes the selected candidates into the lab.

Clear terms, in writing.

By contract

Data, results and IP are governed by a written agreement for each project.

Traceable origin

Every plant traceable together with the communities.

Your next plant is waiting.